Targeting RNA adenosine editing and modification enzymes for RNA therapeutics
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2025.05.021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2025. Verfasst von Nikolaos I Vlachogiannis und 4 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Propaedeutic Internal Medicine and Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of A…. Hauptthemen laut MEDLINE: RNA Editing, Adenosine, Adenosine Deaminase. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 562 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: British Heart Foundation, European Research Council, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Adenosine-to-inosine (A-to-I) RNA editing, and N6 methyladenosine (m6A) are among the most abundant modifications in eukaryotic messenger RNA, affecting various aspects of RNA metabolism and cellular function, including proliferation, differentiation, responses to stressors, and cell death. Recent preclinical evidence suggests that both modifications play a significant role in multiple disorders, including infections, chronic inflammatory diseases, and cancer, sparking great interest in their therapeutic potential. Structural characterization of ADARs (adenosine deaminases acting on RNA) and key m6A enzymes has enabled the development of small molecule inhibitors modulating their expression, enzymatic activity, or binding to target RNAs. Herein, we review preclinical evidence supporting the therapeutic benefits of targeting ADARs and m6A enzymes in diverse disease contexts. Small molecule inhibitors of RNA modification enzymes have shown potent anti-proliferative and pro-apoptotic effects in cancer cells, and have successfully inhibited tumor growth in vivo, without evident toxicity, while their combination with immuno-/chemotherapeutics displayed synergistic anti-neoplastic action. Adenosine RNA editing via recruitment of endogenous ADARs and usage of guide RNAs showed remarkable efficacy in correcting G-to-A point mutations and restoring the associated protein expression with limited off-target activity. Future studies are warranted to evaluate the safety and clinical efficacy of RNA editing or modification-targeting therapeutics in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Propaedeutic Internal Medicine and Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Cardiovascular Research, European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
- Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
- Department of Cardiovascular Research, European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mann…
Förderung
- British Heart Foundation
- European Research Council
- Deutsche Forschungsgemeinschaft
- The Royal Society
- Universität Heidelberg
- Horizon 2020 Framework Programme
- MDC
- Helmholtz Association
Zitieren
APA
Vlachogiannis, N. I., Polycarpou-Schwarz, M., Avdi, A. P., Tual-Chalot, S., & Stellos, K. (2025). Targeting RNA adenosine editing and modification enzymes for RNA therapeutics. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.05.021
Vancouver
Vlachogiannis NI, Polycarpou-Schwarz M, Avdi AP, Tual-Chalot S, Stellos K. Targeting RNA adenosine editing and modification enzymes for RNA therapeutics. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.05.021
BibTeX
@article{Vlachogiannis2025,
author = {Vlachogiannis, Nikolaos I and Polycarpou-Schwarz, Maria and Avdi, Aikaterini-Paraskevi and Tual-Chalot, Simon and Stellos, Konstantinos},
title = {Targeting RNA adenosine editing and modification enzymes for RNA therapeutics},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2025.05.021}
}
EUVIMED